Beneficial effect of proteases on allograft arteriosclerosis in a rat aortic model

Nephrology Dialysis Transplantation

Volumn 11, Issue 6, 1996, Pages 987-989

  Gaciong, Z ^a   Paczek, L ^a   Bojakowski, K ^a   Socha, K ^a   Wisniewski, M ^a   Heidland, A ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Aortic transplant; Bromelain; Neointimal formation; Rejection; Trypsin

Indexed keywords

BROMELAIN; PHLOGENZYM; PROTEINASE; RUTOSIDE; TRYPSIN; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ADVENTITIA; ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA GRAFT; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTERY WALL; ARTICLE; CELL DENSITY; DRUG EFFECT; ELASTIC FIBER; ENZYME THERAPY; INFLAMMATORY INFILTRATE; INTIMA; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0029944251     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/11.6.987     Document Type: Article

References (17)

1. Nakazawa M, Emancipator SN, Lamm ME. Removal of glomerular immune complexes in passive serum thickness nephritis by treatment in vivo with proteolytic enzymes. Lab Invest 1986; 55: 551-556
2. Ohnishi H. The effect of pepsin on autologous immune complex glomerulonephritis. Life Sci 1988; 33: 671-677
3. Gesualdo L, Ricanati S, Hassan MO, Emancipator SN, Lamm ME. Enzymolysis of glomerular immune deposits in vivo with dextranase/protease ameliorates proteinuria, hematuria and mesangial proliferation in murine experimental IgA nephropathy. J Clin Invest 1990; 86: 715-722
4. White RB, Lowrie L, Stork JE, Iskandar SS, Lamm ME, Emancipator SN. Targeted enzyme therapy of experimental glomerulonephritis in rats. J Clin Invest 1991; 87: 1819-1827
5. McKelvey EJ, Urankar-Nagy NJ, White RB, Lamm ME, Emancipator SN. Protease therapy diminishes glomerulosclerosis in a rat model of chronic membranous glomerulonephritis. J Clin Invest (in press)
6. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today 1995; 16: 27-33
7. Plissonier D, Levy BI, Salzmann J-L, Nochy D, Watelet J, Michel J-B. Allograft-induced arterial wall injury and response in normotensive and spontaneously hypertensive rats. Arterioscler Thromb 1991; 11: 1690-1699
8. Isik FF, McDonald TO, Fergusson M, Yamanaka E, Gordon D. Transplant arteriosclerosis in a rat model. Am J Pathol 1992; 141: 1139-1149
9. Sokolowski-Raisanen A, Yilmaz S, Tufvson G, Hayry P. Partial inhibition of allograft arteriosclerosis (chronic rejection) by 15-deoxyspergualin. Transplantation 1994; 57: 1772-1777
10. Plissonier D, Amichot G, Lecagneux J, Duriez M, Gentric D, Michel J-B. Additive and synergistic effects of a low-molecular-weight, heparin-like molecule and low doses of cyclosporin in preventing arterial graft rejection in rats. Arterioscler Thromb 1993; 13: 112-119
11. Plissonier D, Amichot G, Lecagneux J, Duriez M, Gentric D, Michel J-B. Effect of converting enzyme inhibition on allograft-induced arterial wall injury and response. Hypertension 1991; 18 [suppl 1]: 1147-1154
12. Sokolowski-Raisanen A, Tilly-Kiesi M, Ustinov J, Mennander A, Paavonen T, Hayry P. Hyperlipidemia accelerates allograft arteriosclerosis (chronic rejection) in the rat. Arterioscler Thromb 1994; 14: 2032-2042
13. Hale P, Haynes BF. Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, and Leu8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation. J Immunol 1992; 129: 3809-3816
14. Targoni O, Lehman PV. Modulation of activation threshold for autoreactive T cells via systematic enzyme therapy with Phlogenzym. J Neuroimmunol 1995; [suppl. 1]: 66a. (Abstr.)
15. Gibbons G, Dzau VJ. The emerging concept of vascular remodelling. N Engl J Med 1994; 320: 1431-1438
16. Gallis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerosis plaques. J Clin Invest 1994; 94: 2493-2503
17. Falk E, Shah PS, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671